AveXis Inc. (NASDAQ:AVXS) – Analysts at Jefferies Group increased their Q3 2016 earnings per share (EPS) estimates for AveXis in a report issued on Monday. Jefferies Group analyst B. Amin now expects that the firm will post earnings per share of ($0.70) for the quarter, up from their previous forecast of ($0.73). Jefferies Group has a “Buy” rating and a $50.00 price objective on the stock. Jefferies Group also issued estimates for AveXis’ Q4 2016 earnings at ($0.64) EPS, FY2016 earnings at ($3.11) EPS, FY2017 earnings at ($2.85) EPS, FY2018 earnings at ($2.91) EPS, FY2019 earnings at ($2.96) EPS and FY2020 earnings at ($0.32) EPS.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, August 11th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.09.

Several other research analysts have also recently weighed in on AVXS. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Friday, June 24th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of AveXis in a report on Friday, August 12th. Finally, Wells Fargo & Co. initiated coverage on shares of AveXis in a report on Friday, July 15th. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $47.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/q3-2016-eps-estimates-for-avexis-inc-avxs-increased-by-analyst.html

Shares of AveXis (NASDAQ:AVXS) traded down 4.76% on Wednesday, reaching $42.63. 368,260 shares of the company traded hands. The stock has a 50 day moving average of $37.48 and a 200 day moving average of $34.03. The stock’s market cap is $981.04 million. AveXis has a 52-week low of $17.40 and a 52-week high of $47.76.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVXS. Foresite Capital Management III LLC bought a new position in AveXis during the first quarter valued at $4,582,000. TIAA CREF Investment Management LLC acquired a new position in shares of AveXis during the first quarter valued at approximately $253,000. BlackRock Inc. acquired a new position in shares of AveXis during the first quarter valued at approximately $563,000. BlackRock Group LTD acquired a new position in shares of AveXis during the first quarter valued at approximately $2,223,000. Finally, BlackRock Fund Advisors acquired a new position in shares of AveXis during the first quarter valued at approximately $3,245,000. Institutional investors own 54.46% of the company’s stock.

In other news, insider Paul B. Manning sold 289,855 shares of the company’s stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $34.50, for a total value of $9,999,997.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

AveXis Company Profile

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.